Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
Title:
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pol and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
Author:
García, Felipe Bernaldo de Quirós, Juan Carlos López Gómez, Carmen E. Perdiguero, Beatriz Nájera, Jose L. Jiménez, Victoria García-Arriaza, Juan Guardo, Alberto C. Pérez, Iñaki Díaz-Brito, Vicens Conde, Matilde Sánchez González, Nuria Alvarez, Amparo Alcamí, José Jiménez, José Luis Pich, Judit Arnaiz, Joan Albert Maleno, María J. León, Agathe Muñoz-Fernández, María Angeles Liljeström, Peter Weber, Jonathan Pantaleo, Giuseppe Gatell, José M. Plana, Montserrat Esteban, Mariano